Dyadic International Inc Cash Flow Conversion Efficiency
Dyadic International Inc cash flow conversion efficiency. Based on the latest financial reports, Dyadic International Inc (DYAI) has a cash flow conversion efficiency ratio of -0.710x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.85 Million) by net assets ($2.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Dyadic International Inc (2003–2024)
Cash flow conversion efficiency of Dyadic International Inc from 2003 to 2024. This chart illustrates how Dyadic International Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Dyadic International Inc (DYAI) stock price for real-time trading data and today's change.
Dyadic International Inc Cash Flow Conversion Ratio Explained
Dyadic International Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Dyadic International Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dyadic International Inc ranked by their cash flow conversion efficiency. Also see market cap of Dyadic International Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stallion Uranium Corp.
V:STUD
|
-0.034x |
|
Park Ha Biological Technology Co., Ltd.
NASDAQ:PHH
|
-12.940x |
|
The Hain Celestial Group Inc
NASDAQ:HAIN
|
0.178x |
|
NanoCMS Co. Ltd.
KQ:247660
|
0.046x |
|
Moleculin Biotech Inc
NASDAQ:MBRX
|
-0.358x |
|
Reborn Coffee Inc
NASDAQ:REBN
|
-2.774x |
|
Scilex Holding Company
NASDAQ:SCLX
|
0.022x |
|
Nafpaktos Textile Industry S.A
AT:NAYP
|
0.024x |
Annual Cash Flow Conversion Efficiency for Dyadic International Inc (2003–2024)
The table below shows the annual cash flow conversion efficiency of Dyadic International Inc from 2003 to 2024. Review DYAI FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.47 Million | $-3.97 Million | -1.609x | -40.62% |
| 2023-12-31 | $5.88 Million | $-6.73 Million | -1.144x | -56.95% |
| 2022-12-31 | $11.09 Million | $-8.08 Million | -0.729x | -18.90% |
| 2021-12-31 | $18.39 Million | $-11.28 Million | -0.613x | -165.32% |
| 2020-12-31 | $28.45 Million | $-6.57 Million | -0.231x | -43.33% |
| 2019-12-31 | $35.86 Million | $-5.78 Million | -0.161x | -55.31% |
| 2018-12-31 | $42.45 Million | $-4.41 Million | -0.104x | -99.07% |
| 2017-12-31 | $49.98 Million | $-2.61 Million | -0.052x | +50.15% |
| 2016-12-31 | $57.69 Million | $-6.04 Million | -0.105x | -861.81% |
| 2015-12-31 | $73.79 Million | $-802.67K | -0.011x | -100.40% |
| 2014-12-31 | $-2.26 Million | $-6.20 Million | 2.738x | +37.97% |
| 2013-12-31 | $2.57 Million | $5.10 Million | 1.984x | +871.06% |
| 2012-12-31 | $1.79 Million | $365.17K | 0.204x | -95.50% |
| 2011-12-31 | $-800.00K | $-3.63 Million | 4.538x | +244.91% |
| 2010-12-31 | $2.44 Million | $-7.64 Million | -3.131x | -432.71% |
| 2009-12-31 | $6.96 Million | $6.55 Million | 0.941x | +110.68% |
| 2008-12-31 | $1.46 Million | $-12.87 Million | -8.815x | -687.58% |
| 2007-12-31 | $13.50 Million | $-15.11 Million | -1.119x | -4091.22% |
| 2006-12-31 | $28.19 Million | $790.51K | 0.028x | +105.52% |
| 2005-12-31 | $15.38 Million | $-7.82 Million | -0.508x | -111.04% |
| 2004-12-31 | $24.57 Million | $-5.92 Million | -0.241x | -113.89% |
| 2003-12-31 | $-74.09K | $-128.49K | 1.734x | -- |
About Dyadic International Inc
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and la… Read more